Prevention & Treatment of Surgical Site Infections

Injectable, biodegradable local sustained release of antibiotics for prevention & treatment of infections

The Problem

The Need

Learn more about our solution

Market Insights

Surgical Site Infections (SSI)

The most common hospital-acquired infections

SSI average time and care cost

9.7 days of hospital stay and $20,842 per admission

Annual estimated SSI cases in the US

300,000 cases with annual cost of $10B

Sales of SSI prevention products

Expected to exceed $5.5B in 2023


GentaGel, a local slow-release antibiotic treatment is injected and continuously releases antibiotics (e.g., Gentamicin) for up to 60 days.

The antibiotic is not detectable in circulation but achieves sufficient therapeutic concentrations in the administered area.

GentaGel assists patients, doctors and the entire healthcare system



Health System

GentaGel's Inventor and Co-Founder

Prof. Avi Domb

Currently is the Chief Scientist Ministry of Science and Technology of Israel.

B.Sc degrees in Chemistry (Bar Ilan, 1978), Pharmacy (Hebrew Universiry, 1984) and Law (Hebrew University, 2007). Diploma in Polymer and Textile Chemistry (Hebrew Universiry, 1980), Executive business management (Hebrew Universiry, 1997) and a Ph.D. in Organic Chemistry (Hebrew Universiry, 1985). Postdoctoral Fellowship at Syntex Reseach (1984-5), Harvard Medical School Department of Surgery in the Children’s hospital (1985-6) and Department of Chemical Engineering, M.I.T (1986-7).